Item 8.01. Other Events.

On January 6, 2023, Novan, Inc. (the "Company") issued a press release announcing the submission of a New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum. The full text of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On January 6, 2023, the Company also published a corporate presentation on its website at www.Novan.com. The corporate presentation is filed as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

© Edgar Online, source Glimpses